Novan Inc
F:6LUA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Trustmark Corp
NASDAQ:TRMK
|
US |
|
E
|
Esi SpA
MIL:ESI
|
IT |
|
Samudera Indonesia Tbk PT
IDX:SMDR
|
ID |
|
Amrutanjan Health Care Ltd
NSE:AMRUTANJAN
|
IN |
|
Brady Corp
NYSE:BRC
|
US |
|
Sika AG
SIX:SIKA
|
CH |
|
Go Fashion (India) Ltd
NSE:GOCOLORS
|
IN |
|
TYMLEZ Group Ltd
ASX:TYM
|
AU |
|
C
|
China Infrastructure & Logistics Group Ltd
HKEX:1719
|
HK |
|
I
|
Immsi SpA
MIL:IMS
|
IT |
|
China New Higher Education Group Ltd
HKEX:2001
|
CN |
|
Huajin International Holdings Ltd
HKEX:2738
|
CN |
|
Seazen Group Ltd
HKEX:1030
|
CN |
|
LSI Industries Inc
NASDAQ:LYTS
|
US |
|
R C M Technologies Inc
NASDAQ:RCMT
|
US |
|
J
|
Jiangmen Kanhoo Industry Co Ltd
SZSE:300340
|
CN |
|
L
|
Lubawa SA
WSE:LBW
|
PL |
|
Shanghai Haohai Biological Technology Co Ltd
SSE:688366
|
CN |
|
N
|
Netbay PCL
SET:NETBAY
|
TH |
|
Transrail Lighting Ltd
NSE:TRANSRAILL
|
IN |
|
Surrozen Inc
NASDAQ:SRZN
|
US |
|
Monarch Networth Capital Ltd
NSE:MONARCH
|
IN |
|
A
|
Anhui Conch Material Technology Co Ltd
HKEX:2560
|
CN |
|
A
|
Aeris Industria e Comercio de Equipamentos para Geracao de Energia SA
BOVESPA:AERI3
|
BR |
Novan Inc
Short-Term Debt
Novan Inc
Short-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Short-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Novan Inc
F:6LUA
|
Short-Term Debt
$10.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Short-Term Debt
$6.5B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Short-Term Debt
$284m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Pfizer Inc
NYSE:PFE
|
Short-Term Debt
$157m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
N/A
|
|
|
Merck & Co Inc
NYSE:MRK
|
Short-Term Debt
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Short-Term Debt
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Novan Inc
Glance View
Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. The company is headquartered in Durham, North Carolina and currently employs 29 full-time employees. The company went IPO on 2016-09-21. The firm is engaged in researching, developing and marketing products for skin diseases. The firm is focused on dermatology and anti-infective therapies. Its technology platform leverages nitric oxide’s naturally occurring anti-viral, anti-bacterial, anti-fungal, and immunomodulatory mechanisms of action to treat a range of diseases. The firm has clinical-stage dermatology and anti-infective drug candidates with multi-factorial (SB204), anti-viral (SB206), anti-fungal (SB208), and anti-inflammatory (SB414) mechanisms of action. The Company’s lead product candidate is SB206, which is a topical gel with anti-viral properties for the treatment of viral skin infections, with focus on molluscum contagiosum. The firm is exploring the potential of its NITRICIL technology as a potential treatment option for COVID-19, targeting the reduction of viral shedding and transmission.
See Also
What is Novan Inc's Short-Term Debt?
Short-Term Debt
10.3m
USD
Based on the financial report for Dec 31, 2022, Novan Inc's Short-Term Debt amounts to 10.3m USD.
